PolyNovo Revises PMA Submission Timeline to End of 2026 Amid FDA Guidance Changes

Clinical Study Report Completion Marks Key Milestone

PolyNovo Limited (ASX:PNV) has reached an important milestone by finalising the Clinical Study Report (CSR) for its US pivotal randomised controlled trial (RCT) of NovoSorb BTM. This trial, funded by BARDA, targets an on-label indication for full thickness burns in the United States. The CSR incorporates 12-month patient follow-up data, supporting the company’s progression towards Premarket Approval (PMA) submission.

While the CSR completion is a significant step, PolyNovo’s CEO Bruce Peatey emphasised a cautious and quality-driven approach, noting the company’s commitment to meeting both FDA expectations and internal standards.

FDA Guidance Update Triggers Submission Plan Revision

In February 2026, the FDA introduced updated guidance on quality management system (QMS) requirements for PMA submissions. PolyNovo responded by revisiting its submission strategy, expanding the scope and sequencing of manufacturing and validation activities. This led to the decision to include certain manufacturing processes and validation documentation originally planned for after submission into the PMA package itself.

This proactive adjustment aims to enhance the robustness of the submission and inspection readiness, aligning with evolving regulatory expectations. The revised plan also allows the inclusion of 18-month follow-up data, a prerequisite for PMA approval, without affecting the FDA’s review timeline.

PolyNovo’s recent appointment of Allison Myers as Chief Quality & Regulatory Affairs Officer underscores the company’s focus on quality and regulatory compliance as it prepares for this critical regulatory milestone.

PMA Submission Now Expected by Year-End 2026

The company now anticipates submitting its full PMA application before the end of calendar 2026, a shift from earlier mid-2026 expectations. This delay is driven by the need to incorporate additional manufacturing validation and the 18-month patient data, rather than any clinical or commercial setbacks.

Importantly, this timeline revision does not impact current sales or clinical use of NovoSorb products, which continue to see strong demand from clinicians under existing approvals. This stability in commercial operations is notable given PolyNovo’s recent robust 25% revenue surge amid ongoing FDA preparations.

Strategic Quality Focus Supports Long-Term US Growth

PolyNovo’s disciplined approach to the PMA submission reflects a broader strategy to secure long-term success in the US market. The company has prioritised completing, validating, and documenting key manufacturing and supplier processes ahead of submission, aiming for a review-ready package that meets stringent FDA standards.

This focus on quality and compliance comes as PolyNovo continues to expand its footprint, building on recent infrastructure investments and leadership changes, including the appointment of Bruce Peatey as CEO last year to drive global expansion and innovation.